Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

359 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The site of breast cancer metastases dictates their clonal composition and reversible transcriptomic profile.
Berthelet J, Wimmer VC, Whitfield HJ, Serrano A, Boudier T, Mangiola S, Merdas M, El-Saafin F, Baloyan D, Wilcox J, Wilcox S, Parslow AC, Papenfuss AT, Yeo B, Ernst M, Pal B, Anderson RL, Davis MJ, Rogers KL, Hollande F, Merino D. Berthelet J, et al. Among authors: yeo b. Sci Adv. 2021 Jul 7;7(28):eabf4408. doi: 10.1126/sciadv.abf4408. Print 2021 Jul. Sci Adv. 2021. PMID: 34233875 Free PMC article.
A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer.
Lok SW, Whittle JR, Vaillant F, Teh CE, Lo LL, Policheni AN, Bergin ART, Desai J, Ftouni S, Gandolfo LC, Liew D, Liu HK, Mann GB, Moodie K, Murugasu A, Pal B, Roberts AW, Rosenthal MA, Shackleton K, Silva MJ, Siow ZR, Smyth GK, Taylor L, Travers A, Yeo B, Yeung MM, Bujak AZ, Dawson SJ, Gray DHD, Visvader JE, Lindeman GJ. Lok SW, et al. Among authors: yeo b. Cancer Discov. 2019 Mar;9(3):354-369. doi: 10.1158/2159-8290.CD-18-1151. Epub 2018 Dec 5. Cancer Discov. 2019. PMID: 30518523 Clinical Trial.
Computational Screening of Anti-Cancer Drugs Identifies a New BRCA Independent Gene Expression Signature to Predict Breast Cancer Sensitivity to Cisplatin.
Berthelet J, Foroutan M, Bhuva DD, Whitfield HJ, El-Saafin F, Cursons J, Serrano A, Merdas M, Lim E, Charafe-Jauffret E, Ginestier C, Ernst M, Hollande F, Anderson RL, Pal B, Yeo B, Davis MJ, Merino D. Berthelet J, et al. Among authors: yeo b. Cancers (Basel). 2022 May 13;14(10):2404. doi: 10.3390/cancers14102404. Cancers (Basel). 2022. PMID: 35626009 Free PMC article.
Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations.
Lopez-Knowles E, Pearson A, Schuster G, Gellert P, Ribas R, Yeo B, Cutts R, Buus R, Garcia-Murillas I, Haynes B, Martin LA, Smith I, Turner N, Dowsett M. Lopez-Knowles E, et al. Among authors: yeo b. Br J Cancer. 2019 Jan;120(2):247-255. doi: 10.1038/s41416-018-0345-x. Epub 2018 Dec 19. Br J Cancer. 2019. PMID: 30563991 Free PMC article.
Ectopic breast cancer in the inguinal region.
Loh Z, Yeo B, Williams DS, Gyorki DE. Loh Z, et al. Among authors: yeo b. Breast J. 2019 Jan;25(1):155-156. doi: 10.1111/tbj.13177. Epub 2018 Dec 27. Breast J. 2019. PMID: 30592120 No abstract available.
Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer.
Kanjanapan Y, Lok SW, Gibbs P, De Boer R, Yeo B, Greenberg S, Barnett F, Knott L, Richardson G, Wong R, Nottage M, Collins IM, Torres J, Lombard J, Johns J, Harold M, Malik L. Kanjanapan Y, et al. Among authors: yeo b. Breast Cancer Res Treat. 2020 Nov;184(1):87-95. doi: 10.1007/s10549-020-05825-w. Epub 2020 Aug 10. Breast Cancer Res Treat. 2020. PMID: 32779037
359 results